PP
BHVN

Paloma Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Paloma Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,458
Closed -$1.24M – 2505
2020
Q4 		$1.24M Buy
+14,458
New +$1.23M 0.03% 500

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paloma Partners's BHVN Position: Q1 2021 in Review

Paloma Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 14,458 shares — an estimated $1.24M sold.

Paloma Partners first reported a position in BHVN in Q4 2020 and held it in 1 quarter. The position peaked at $1.24M in Q4 2020. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

  • Paloma Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
  • Paloma Partners sold 14,458 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $1.24M.
  • Paloma Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 1 quarter.
  • Paloma Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.24M in Q4 2020.
  • 224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Paloma Partners's 13F filing for Q1 2021, filed 17 May 2021.